IQVIA Announces Multi-Year Agreement With argenx SE For Development Of New Indications For VYVGART
IQVIA (NYSE:IQV) announced an agreement today with argenx SE. The multi-year contract covers a unique collaboration for the development of new indications for VYVGART™ (efgartigimod alfa fcab), an FDA-approved